Antihemophilic factor, human recombinant
- Generic Name
- Antihemophilic factor, human recombinant
- Brand Names
- Advate, Adynovate, Helixate, Kogenate, Kovaltry, Novoeight, Recombinate
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 139076-62-3
- Unique Ingredient Identifier
- P89DR4NY54
- Background
Human recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells
- Indication
The human recombinant antihemophilic factor is indicated for use in adults and children with hemophilia A for the control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
- Associated Conditions
- Bleeding, Joint Damage, Perioperative Blood Loss
- Associated Therapies
- -
Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 13
- Registration Number
- NCT05042440
- Locations
- 🇧🇬
Investigational Site Number :1000001, Sofia, Bulgaria
Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using myPKFiT®
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Spanish Society of Thrombosis and Haemostasis
- Target Recruit Count
- 50
- Registration Number
- NCT03006965
- Locations
- 🇪🇸
Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain
🇪🇸Hospital Virgen del Camino, Pamplona, Navarra, Spain
🇪🇸Hospital Xeral de Vigo, Vigo, Pontevedra, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath